Rankings
▼
Calendar
ALNY Q1 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
Q1 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
Gross Profit
$7M
100.0% margin
Operating Income
-$110M
-1498.0% margin
Net Income
-$103M
-1402.0% margin
EPS (Diluted)
$-1.21
Cash Flow
Operating Cash Flow
-$84M
Free Cash Flow
-$95M
Stock-Based Comp.
$23M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$128M
Stockholders' Equity
$1.2B
Cash & Equivalents
$231M
← FY 2016
All Quarters
Q2 2016 →
